 Leonard Seibold
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 33 | 2023 | 202 | 8.040 |
Why?
| | Glaucoma, Open-Angle | 20 | 2023 | 95 | 7.190 |
Why?
| | Intraocular Pressure | 44 | 2023 | 275 | 6.830 |
Why?
| | Trabeculectomy | 15 | 2022 | 65 | 4.010 |
Why?
| | Phacoemulsification | 12 | 2023 | 103 | 3.990 |
Why?
| | Cataract | 10 | 2023 | 194 | 3.060 |
Why?
| | Ocular Hypertension | 7 | 2022 | 60 | 2.920 |
Why?
| | Glaucoma Drainage Implants | 9 | 2022 | 47 | 2.570 |
Why?
| | Tonometry, Ocular | 22 | 2022 | 83 | 2.200 |
Why?
| | Visual Acuity | 11 | 2022 | 272 | 2.020 |
Why?
| | Trabecular Meshwork | 7 | 2019 | 75 | 1.670 |
Why?
| | Glaucoma, Angle-Closure | 2 | 2020 | 16 | 1.400 |
Why?
| | Ophthalmology | 4 | 2023 | 80 | 1.230 |
Why?
| | Cataract Extraction | 5 | 2020 | 82 | 1.210 |
Why?
| | Laser Therapy | 3 | 2018 | 104 | 1.210 |
Why?
| | Ophthalmic Solutions | 6 | 2018 | 66 | 0.980 |
Why?
| | Filtering Surgery | 6 | 2016 | 22 | 0.940 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 437 | 0.940 |
Why?
| | Lens Implantation, Intraocular | 3 | 2018 | 60 | 0.900 |
Why?
| | Perception | 3 | 2021 | 313 | 0.800 |
Why?
| | Nerve Fibers | 2 | 2012 | 89 | 0.790 |
Why?
| | Retinal Ganglion Cells | 2 | 2012 | 92 | 0.780 |
Why?
| | Tomography, Optical Coherence | 2 | 2012 | 126 | 0.770 |
Why?
| | Stents | 4 | 2021 | 457 | 0.740 |
Why?
| | Laser Coagulation | 3 | 2023 | 55 | 0.720 |
Why?
| | Legislation, Drug | 1 | 2020 | 78 | 0.710 |
Why?
| | Specialization | 1 | 2020 | 120 | 0.700 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 11 | 0.690 |
Why?
| | Pilocarpine | 1 | 2018 | 8 | 0.670 |
Why?
| | Ciliary Body | 2 | 2018 | 33 | 0.670 |
Why?
| | Medical Marijuana | 1 | 2020 | 102 | 0.650 |
Why?
| | Angiogenesis Inhibitors | 5 | 2020 | 219 | 0.630 |
Why?
| | Marijuana Use | 1 | 2020 | 157 | 0.610 |
Why?
| | Brimonidine Tartrate | 1 | 2017 | 9 | 0.600 |
Why?
| | Thiazines | 1 | 2017 | 9 | 0.600 |
Why?
| | Prospective Studies | 11 | 2021 | 6471 | 0.600 |
Why?
| | Timolol | 1 | 2017 | 14 | 0.600 |
Why?
| | Marijuana Smoking | 1 | 2020 | 220 | 0.590 |
Why?
| | Burnout, Professional | 1 | 2022 | 330 | 0.580 |
Why?
| | Sulfonamides | 2 | 2017 | 445 | 0.580 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2013 | 24 | 0.580 |
Why?
| | Retrospective Studies | 21 | 2023 | 12972 | 0.580 |
Why?
| | Humans | 60 | 2023 | 118931 | 0.570 |
Why?
| | Endoscopy | 2 | 2018 | 272 | 0.560 |
Why?
| | Corneal Diseases | 1 | 2016 | 36 | 0.550 |
Why?
| | Endophthalmitis | 1 | 2016 | 25 | 0.550 |
Why?
| | Circadian Rhythm | 2 | 2023 | 401 | 0.540 |
Why?
| | Aged, 80 and over | 12 | 2019 | 6555 | 0.530 |
Why?
| | Aged | 18 | 2021 | 19644 | 0.500 |
Why?
| | Ocular Hypotension | 3 | 2022 | 10 | 0.480 |
Why?
| | Cloprostenol | 1 | 2013 | 12 | 0.480 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1284 | 0.470 |
Why?
| | Physicians | 1 | 2022 | 792 | 0.470 |
Why?
| | Postoperative Period | 6 | 2019 | 309 | 0.460 |
Why?
| | Prosthesis Implantation | 4 | 2022 | 141 | 0.460 |
Why?
| | Drug Combinations | 3 | 2020 | 291 | 0.440 |
Why?
| | Benzalkonium Compounds | 1 | 2012 | 14 | 0.440 |
Why?
| | Middle Aged | 18 | 2020 | 27607 | 0.430 |
Why?
| | Wound Healing | 2 | 2012 | 270 | 0.390 |
Why?
| | Adipocytes | 1 | 2012 | 199 | 0.390 |
Why?
| | Blood Pressure | 2 | 2017 | 1664 | 0.380 |
Why?
| | Optic Disk | 1 | 2010 | 36 | 0.380 |
Why?
| | Stainless Steel | 1 | 2010 | 21 | 0.380 |
Why?
| | Female | 25 | 2023 | 61547 | 0.380 |
Why?
| | Male | 24 | 2021 | 57784 | 0.380 |
Why?
| | Contact Lenses | 2 | 2020 | 8 | 0.360 |
Why?
| | Uveitis | 2 | 2022 | 116 | 0.360 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 1974 | 0.340 |
Why?
| | Prednisolone | 2 | 2020 | 76 | 0.320 |
Why?
| | Software | 1 | 2012 | 613 | 0.320 |
Why?
| | Treatment Outcome | 12 | 2022 | 9341 | 0.310 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2019 | 158 | 0.300 |
Why?
| | Vision Disorders | 2 | 2020 | 135 | 0.300 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 4551 | 0.270 |
Why?
| | Sleep | 2 | 2023 | 660 | 0.270 |
Why?
| | Alkylating Agents | 2 | 2016 | 25 | 0.250 |
Why?
| | Glaucoma, Neovascular | 2 | 2015 | 10 | 0.250 |
Why?
| | Glucocorticoids | 2 | 2020 | 545 | 0.240 |
Why?
| | Reproducibility of Results | 3 | 2021 | 2874 | 0.240 |
Why?
| | Macular Edema | 1 | 2023 | 36 | 0.230 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 79 | 0.220 |
Why?
| | Communication Barriers | 1 | 2023 | 94 | 0.210 |
Why?
| | Adult | 13 | 2020 | 31508 | 0.210 |
Why?
| | Diabetic Retinopathy | 1 | 2023 | 160 | 0.200 |
Why?
| | Heart Rate | 2 | 2017 | 727 | 0.200 |
Why?
| | Manometry | 1 | 2021 | 89 | 0.200 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.190 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.190 |
Why?
| | Gonioscopy | 1 | 2020 | 6 | 0.190 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 14 | 0.190 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.190 |
Why?
| | Health Status Disparities | 1 | 2023 | 209 | 0.190 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 25 | 0.190 |
Why?
| | Follow-Up Studies | 5 | 2022 | 4596 | 0.190 |
Why?
| | Language | 1 | 2023 | 271 | 0.190 |
Why?
| | Amyloidosis | 1 | 2020 | 40 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 527 | 0.190 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2020 | 36 | 0.190 |
Why?
| | Visual Fields | 1 | 2020 | 78 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 2 | 2014 | 3174 | 0.180 |
Why?
| | Retinal Diseases | 1 | 2020 | 81 | 0.180 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 4705 | 0.180 |
Why?
| | Eye Diseases | 1 | 2020 | 77 | 0.180 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 380 | 0.180 |
Why?
| | Intraoperative Complications | 1 | 2020 | 131 | 0.170 |
Why?
| | Biosensing Techniques | 1 | 2020 | 107 | 0.170 |
Why?
| | Preoperative Period | 1 | 2019 | 110 | 0.170 |
Why?
| | Mitomycin | 2 | 2016 | 27 | 0.170 |
Why?
| | Axial Length, Eye | 1 | 2018 | 9 | 0.160 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.160 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.160 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.160 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 11 | 0.160 |
Why?
| | Refraction, Ocular | 1 | 2018 | 31 | 0.160 |
Why?
| | United States | 4 | 2023 | 12541 | 0.160 |
Why?
| | Time Factors | 2 | 2019 | 6409 | 0.160 |
Why?
| | Young Adult | 5 | 2019 | 10793 | 0.150 |
Why?
| | Intravitreal Injections | 4 | 2020 | 46 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2023 | 495 | 0.150 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 16 | 0.150 |
Why?
| | Equipment Design | 1 | 2018 | 519 | 0.140 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 306 | 0.140 |
Why?
| | Fluoroquinolones | 1 | 2016 | 42 | 0.140 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 647 | 0.130 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 11 | 0.130 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 103 | 0.130 |
Why?
| | Drug Packaging | 1 | 2015 | 44 | 0.130 |
Why?
| | Device Removal | 1 | 2016 | 127 | 0.130 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 6 | 0.120 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2014 | 60 | 0.120 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 21 | 0.120 |
Why?
| | Travoprost | 1 | 2013 | 12 | 0.120 |
Why?
| | Patient Preference | 1 | 2016 | 170 | 0.120 |
Why?
| | Antimetabolites | 1 | 2012 | 25 | 0.110 |
Why?
| | Telemedicine | 1 | 2021 | 660 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 652 | 0.110 |
Why?
| | Anterior Chamber | 1 | 2012 | 21 | 0.110 |
Why?
| | Adenoma | 1 | 2014 | 191 | 0.110 |
Why?
| | Conjunctiva | 1 | 2012 | 52 | 0.100 |
Why?
| | Blister | 1 | 2012 | 39 | 0.100 |
Why?
| | Prostaglandins F | 1 | 2011 | 18 | 0.100 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 21 | 0.100 |
Why?
| | Equipment Safety | 1 | 2010 | 38 | 0.090 |
Why?
| | Tissue Donors | 1 | 2012 | 336 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 555 | 0.090 |
Why?
| | Torque | 1 | 2010 | 67 | 0.090 |
Why?
| | Dexamethasone | 1 | 2012 | 320 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2173 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 965 | 0.090 |
Why?
| | Cell Survival | 1 | 2012 | 1047 | 0.090 |
Why?
| | Reference Values | 1 | 2010 | 774 | 0.090 |
Why?
| | Cohort Studies | 1 | 2019 | 5116 | 0.080 |
Why?
| | Adolescent | 4 | 2020 | 18480 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 681 | 0.080 |
Why?
| | Inflammation | 1 | 2018 | 2566 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1510 | 0.070 |
Why?
| | Administration, Topical | 2 | 2016 | 141 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2012 | 2275 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2012 | 4076 | 0.060 |
Why?
| | Safety-net Providers | 1 | 2023 | 96 | 0.050 |
Why?
| | Rabbits | 2 | 2012 | 780 | 0.050 |
Why?
| | Coronary Angiography | 1 | 2022 | 311 | 0.040 |
Why?
| | Postoperative Complications | 2 | 2021 | 2235 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 482 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 231 | 0.040 |
Why?
| | Histological Techniques | 1 | 2018 | 43 | 0.040 |
Why?
| | Reoperation | 1 | 2020 | 557 | 0.040 |
Why?
| | Perioperative Care | 1 | 2019 | 132 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3055 | 0.040 |
Why?
| | Microscopy | 1 | 2018 | 125 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 167 | 0.040 |
Why?
| | Fibrosis | 1 | 2018 | 483 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 92 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 271 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1418 | 0.030 |
Why?
| | Iris | 1 | 2013 | 19 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2490 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 462 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1353 | 0.030 |
Why?
| | Goblet Cells | 1 | 2012 | 17 | 0.030 |
Why?
| | Prognosis | 1 | 2020 | 3440 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 161 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 287 | 0.020 |
Why?
| | Postoperative Care | 1 | 2012 | 237 | 0.020 |
Why?
| | Collagen | 1 | 2012 | 433 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1944 | 0.020 |
Why?
| | Animals | 3 | 2012 | 33381 | 0.020 |
Why?
| | Child | 1 | 2020 | 19128 | 0.010 |
Why?
|
|
Seibold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|